March 23rd 2023
Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College
February 16th 2023
Zolbetuximab Combo Meets PFS End Point in CLDN18.2+ HER2– Advanced/Metastatic Gastric/GEJ CancerDecember 31st 2022
Topline results from the phase 3 GLOW trial indicated that zolbetuximab plus CAPOX yielded a statistically significant increase in progression-free survival over placebo/CAPOX.
EU Approves Fam-Trastuzumab Deruxtecan-nxki HER2+ Advanced Gastric CancerDecember 22nd 2022
Patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in the European Union can now receive treatment with fam-trastuzumab deruxtecan-nxki following its approval.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer TypesDecember 15th 2022
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Pembrolizumab/Chemotherapy Meets Survival End Point in HER2– Advanced/Metastatic Gastric/GEJ AdenocarcinomaNovember 22nd 2022
Pembrolizumab plus chemotherapy yielded a significant improvement in overall survival compared with placebo plus chemotherapy in patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Zolbetuximab Reaches PFS End Point in CLDN18.2+ HER2– Advanced/Metastatic Gastric/GEJ AdenocarcinomaNovember 17th 2022
Zolbetuximab and mFOLFOX6 combination therapy demonstrated positive topline efficacy and safety in patients with Claudin 18.2–positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Fruquintinib/Paclitaxel Meets PFS End Point in Second-Line Gastric Cancer TrialNovember 16th 2022
Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.
Bemarituzumab Plus mFOLFOX6 Demonstrates Promising Clinical Efficacy in Advanced Gastric CancerNovember 4th 2022
Data from the phase 2 FIGHT study indicated that the monoclonal antibody bemarituzumab may be a promising treatment when combined with mFOLFOX6 for patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
HCC Related to Nonalcoholic Fatty Liver Disease Vs Other Causes Linked With Lower Rates of Cirrhosis, SurveillanceJune 23rd 2022
Individuals with nonalcoholic fatty liver disease–related hepatocellular carcinoma were found to have lower rates of surveillance vs other potential causes of disease.
CMG901 Granted Fast Track Designation by FDA in Unresectable or Metastatic Relapsed/Refractory Gastric and GEJ CancerApril 27th 2022
Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.
Treating Frontline PD-L1+ Gastric/GEJ Adenocarcinoma With Pembrolizumab Monotherapy or Plus Chemo Results in Similar OS as SOCJanuary 21st 2022
Adding pembrolizumab to chemotherapy does not improve outcomes over chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to updated results of the KEYNOTE-062 trial.
Limited Clinical Activity Attributed to Second-Line Treatment With Linagliptin Plus Atezolizumab in Gastric/GEJ CarcinomaSeptember 16th 2021
Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab.
Certain Genomic Pathways of Gut Microbiome Significantly Associated With Survival in Nivolumab-Treated Patients With Gastric/GEJ CancerSeptember 2nd 2021
Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.
Perioperative Oxaliplatin With S-1 Demonstrates Significant Clinical Activity in Locally Advanced Gastric CancerAugust 23rd 2021
Research suggests that perioperative S-1 plus oxaliplatin in patients with gastric cancer who have had a D2 gastrectomy yields a clinically significant improvement over adjuvant capecitabine plus oxaliplatin.
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Effective in Korean Population With Advanced Gastric CancerJuly 26th 2021
Recent data indicated that the combination of neoadjuvant docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 was effective and tolerable in a population of Korean patients who had locally advanced gastric cancer.
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric CancerApril 16th 2021
The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.
Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer SubgroupApril 10th 2021
Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.
Trastuzumab Deruxtecan Sensitivity Associated With Various Levels of HER2-Expressing Gastric Cancer CellsApril 10th 2021
Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.
Early-Onset Gastric Cancer Suggested to be Genetically and Clinically DistinctJanuary 20th 2020
Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.